An analysis of successful hit-to-clinical candidate pairs

DG Brown - Journal of medicinal chemistry, 2023 - ACS Publications
An analysis of 156 published clinical candidates from the Journal of Medicinal Chemistry
between 2018 and 2021 was conducted to identify lead generation strategies most …

Type 2 inflammation and biological therapies in asthma: Targeted medicine taking flight

I Howell, A Howell, ID Pavord - Journal of Experimental Medicine, 2023 - rupress.org
The field of asthma has undergone a dramatic change in recent years. Advances in our
understanding of type 2 airway inflammation have driven the discovery of monoclonal …

Structures of leukotriene biosynthetic enzymes and development of new therapeutics

JZ Haeggström, ME Newcomer - Annual review of …, 2023 - annualreviews.org
Leukotrienes are potent immune-regulating lipid mediators with patho-genic roles in
inflammatory and allergic diseases, particularly asthma. These autacoids also contribute to …

[HTML][HTML] Identification of selective 5-LOX and FLAP inhibitors as novel anti-inflammatory agents by ligand-based virtual screening

C Cerchia, L Küfner, O Werz, A Lavecchia - European Journal of Medicinal …, 2024 - Elsevier
Inflammation is a multifaceted biological process in which the conversion of arachidonic acid
to eicosanoids, including prostaglandins and leukotrienes (LTs), plays a crucial role. 5 …

Differential impact of 5-lipoxygenase-activating protein antagonists on the biosynthesis of leukotrienes and of specialized pro-resolving mediators

P Dahlke, LK Peltner, PM Jordan, O Werz - Frontiers in Pharmacology, 2023 - frontiersin.org
Lipoxygenases (LOX) transform arachidonic acid (AA, C20: 4) and docosahexaenoic acid
(DHA, C22: 6) into bioactive lipid mediators (LMs) that comprise not only pro-inflammatory …

Molecular pharmacology of inflammation resolution in atherosclerosis

S Kotlyarov, A Kotlyarova - International Journal of Molecular Sciences, 2022 - mdpi.com
Atherosclerosis is one of the most important problems of modern medicine as it is the
leading cause of hospitalizations, disability, and mortality. The key role in the development …

Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase

C Markert, G Thoma, H Srinivas… - Journal of medicinal …, 2021 - ACS Publications
The cytosolic metalloenzyme leukotriene A4 hydrolase (LTA4H) is the final and rate-limiting
enzyme in the biosynthesis of pro-inflammatory leukotriene B4 (LTB4). Preclinical studies …

Regioselective synthesis of C3-hydroxyarylated pyrazoles

L O'Sullivan, KV Patel, BC Rowley… - The Journal of …, 2021 - ACS Publications
Pyrazoles are ubiquitous structures in medicinal chemistry. We report the first regioselective
route to C3-hydroxyarylated pyrazoles obtained through reaction of pyrazole N-oxides with …

Diethanolamine boronic esters: development of a simple and standard process for boronic ester synthesis

PA Inglesby, LR Agnew, HL Carter… - … Process Research & …, 2020 - ACS Publications
Herein, we disclose the unique physical properties of diethanolamine (DEA) boronic esters
that have facilitated the development of a simple and standard process for their synthesis …

Montelukast use decreases cardiovascular events in asthmatics

M Hoxha, CC Tedesco, S Quaglin, V Malaj… - Frontiers in …, 2021 - frontiersin.org
Cysteinyl leukotrienes are proinflammatory mediators with a clinically established role in
asthma and a human genetic and preclinical role in cardiovascular pathology. Given that …